Valuation: BIOLASE, Inc.

Chart: BIOLASE, Inc.

26/08/25	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/05/25	EnVVeno Medical Names Jennifer Bright CFO	MT
05/03/25	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25/02/25	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
21/02/25	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
18/02/25	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
14/02/25	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
29/01/25	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
14/01/25	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
13/01/25	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
08/01/25	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
23/12/24	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
15/11/24	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

01/04/24	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
31/05/23	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
20/01/23	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
20/05/22	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

14/10/25	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
08/11/24	Biolase: Q3 Earnings Snapshot	AQ
08/11/24	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
01/10/24	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
08/08/24	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	09/09/2025
Steven Sandor COO	Chief Operating Officer	46	05/07/2022
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	30/09/2016

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	31/08/2017
Kathleen O'Loughlin BRD	Director/Board Member	75	15/08/2021
Martha Somerman BRD	Director/Board Member	-	15/08/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/09/23	Goldman Sachs & Co. LLC (Private Banking)	Other	Company	144,501	13.8444%
07/06/23	Kenneth Yale	Free	Director	502,404	1.6050%
07/06/23	Carol Summerhays	Free	Director	491,987	1.5717%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE, INC.	-.--%	-.--%	-	-	36
CHURCHILL CAPITAL CORP XI	-5.72%	+26.93%	-	-	950M
CHURCHILL CAPITAL CORP VII	-0.30%	-.--%	-.--%	-3.20%	915M
PRIME BEING CORP.	-35.29%	-.--%	+44.74%	+391.07%	797M
CENTIEL AG	-4.62%	-26.71%	+309.51%	-68.69%	656M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.20%	+0.20%	-	-	641M
ACC AVIATION HOLDINGS LTD.	-1.57%	-1.57%	+1,150.00%	+294.20%	624M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	-.--%	-.--%	-.--%	600M
CHURCHILL CAPITAL CORP XII	-0.28%	+3.56%	-	-	603M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.24%	-0.10%	-	-	599M
Average	-4.61%	+3.11%	+300.85%	+122.68%	638.46M
Weighted average by Cap.	-5.77%	+5.08%	+266.18%	+124.49%